Drugs / BIIB091
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06640933 | Oct 2024 → Feb 2025 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT06574828 | Aug 2024 → Mar 2025 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT06311786 | Apr → May 2024 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT04564612 | Sep 2020 → Sep 2022 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT03943056 | May 2019 → Jan 2020 | — | Biogen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05798520 | Jul 2023 → Feb 2026 | multiple sclerosis | Biogen | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05798520 ↗ |
| Known as | [14C]-BIIB091 | “Participants will receive a single oral dose of \[14C\]-BIIB091 on Day 1.” NCT06311786 ↗ |
| Action | Inhibit | “BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor” NCT03943056 ↗ |
| Modality | Small molecule | — CHEMBL5083772 ↗ |
| Route | Oral | “single and multiple oral doses of BIIB091” NCT03943056 ↗ |
| Target | BTK | “BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor” NCT03943056 ↗ |